Principal Investigator: Charalampos Tzoulis

We recently completed the NAD-PARK study, a trial of tolerability and cerebral bioavailability of NAD supplementation therapy with NR in PD (ClinicalTrials.gov: NCT03816020). A total of 30 individuals with newly diagnosed, drug naïve PD were randomized to NR 500 mg x2/day or placebo for 30 days. Data analyses are ongoing and the first publication is anticipated during 2020 ir early 2021.

Menu
Vi bruker informasjonskapsler for å kunne gi deg den beste brukeropplevelsen. Ved å bla videre på siden aksepterer du at slik informasjon benyttes.
Aksepter